USA Financial Formulas Grows Stake in Encompass Health Co. (NYSE:EHC)

USA Financial Formulas grew its position in Encompass Health Co. (NYSE:EHC) by 7.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,642 shares of the company’s stock after purchasing an additional 240 shares during the quarter. USA Financial Formulas’ holdings in Encompass Health were worth $336,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of EHC. Point72 Asset Management L.P. grew its holdings in Encompass Health by 2,458.5% in the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after purchasing an additional 835,135 shares during the last quarter. Magnetar Financial LLC lifted its stake in shares of Encompass Health by 1,176.6% during the second quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock worth $63,899,000 after buying an additional 814,018 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of Encompass Health by 2,302.7% during the second quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock worth $51,780,000 after buying an additional 578,438 shares during the period. AQR Capital Management LLC lifted its stake in shares of Encompass Health by 213.3% during the second quarter. AQR Capital Management LLC now owns 207,202 shares of the company’s stock worth $17,776,000 after buying an additional 141,075 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Encompass Health by 22.0% during the third quarter. Franklin Resources Inc. now owns 700,021 shares of the company’s stock worth $67,412,000 after buying an additional 126,000 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Trading Up 0.9 %

EHC stock opened at $94.47 on Friday. The company’s 50-day simple moving average is $97.75 and its 200-day simple moving average is $93.87. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health Co. has a 52-week low of $69.72 and a 52-week high of $104.55. The firm has a market cap of $9.52 billion, a P/E ratio of 22.82, a PEG ratio of 1.09 and a beta of 0.89.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.09. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period in the prior year, the company posted $0.86 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities analysts forecast that Encompass Health Co. will post 4.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on EHC. Barclays lifted their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. KeyCorp boosted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. UBS Group boosted their target price on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Truist Financial restated a “buy” rating and set a $116.00 target price (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada boosted their target price on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.